Webinar Recording

Patient-Derived Organoids & Assays for Cancer Research 

Presented on June 8, 2021

With the increasing use of 3D cell structures for modeling tumors, organs, and tissue for translation research, there is a requirement for cancer models, assays and workflows to study patient-derived samples. In this webinar the speakers presented efforts of a successful collaboration of using our automated assay system (the Pu·MA System) with patient-derived organoids for developing an efficient workflow which was incorporated into a translational project which addressed therapeutics and drug resistance in triple negative breast cancer 

Presenters:

Margarite and Katya - Jun 2021

  • Margarite Matossian, MD PhD (Tulane University Medical University)
    Physician-Scientist in the group of Dr. Matthew Burow (Burow Lab website.
    This study was funded by NIH & Krewe de Pink)
    Patient-Derived Organoids: Translational Oncology research to Interrogate Therapeutic Responses & Drug Resistance

 

  • Katya Nikolov, MD (Protein Fluidics, Inc.)
    Senior Application Scientist
    Automated Assays with Patient-Derived Organoids using the Pu·MA System

“They introduced us to this system and allowed us to realize novel applications of our organoid studies. It was surprisingly easy to use which I often told Evan, but it’s very true. The system required only small volumes of tissues and reagents to help us combat our work concerns with tissue availability. We were able to image these studies in well without having to transfer the samples to our imaging system. And then it minimized disruption to the organoids or spheroids using those microfluidics chambers and this is all under sterile conditions. This Pu·MA System fits in your incubator so it’s really easy for us to use, and there were diverse applications with various biological endpoints so we were very happy to collaborate with Protein Fluidics. And furthermore, I just want to hammer home that it is incredibly simple to use. I am not great with technology so for me to say this it must be true. […] The Pu·MA System was able to help us really translate [our] findings better”

-Dr. Margarite Matossian

Learn how:

  • The Pu·MA System can help prevent loss or damage during assay steps such as media exchange, supernatant sampling, or immunofluorescence staining.  
  • Patient-derived organoids were cultured from breast cancer patient samples for studying drug resistance 
  • To use these methods in a simple unified workflow
For previous webinar recordings, check out our Webinars page

Contact Us

Protein Fluidics, Inc.

875 Cowan Road, Suite B,
Burlingame, CA 94010

+1 650 529 5080

info@proteinfluidics.com

#pumasystem  #flowchip  #3dcellassay

Our Company

For Research Use Only. Not for diagnostic use. Protein Fluidics, Protein Fluidics Logo and Pu·MA System are registered trademarks of Protein Fluidics, Inc. in the United States and internationally. All other trademarks belong to their respective owners. All rights reserved. © 2024 PROTEIN FLUIDICS, INC.